Respiratory & Immunology

Following the science to improve patient outcomes

Building on a 50-year heritage in respiratory care, our ambition is to transform the treatment of asthma and chronic obstructive pulmonary disease (COPD) by driving earlier, biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.

Underpinning chronic lung diseases is an altered immune system. AstraZeneca is following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas.

The disease areas we’re targeting include rheumatology (including type 1 interferon-driven diseases such as lupus), dermatology, gastrointestinal diseases and inflammatory diseases driven by eosinophilic immune dysfunction. Our ambition is to achieve disease modification and durable remission in these diseases for millions of patients worldwide.

Advancing the science of Respiratory & Immunology for patients

How can we make the biggest possible difference for patients? Hear from the team at AstraZeneca who are working to advance cutting-edge science and our growing pipeline in Respiratory and Immunology.

Our people

Join Our Team

At AstraZeneca Respiratory & Immunology, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. That difference starts with you. As one of Science Magazine’s 2018 Top Employer, we need people like you who share our passion for science and determination to meet patients’ needs around the world.

Our Pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.

Respiratory & Immunology (as of 10 February 2022)

Phase I

Phase I

  • AZD4604 asthma
  • AZD5055 idiopathic pulmonary fibrosis
  • AZD8630 asthma

Phase II

Phase II

  • AZD1402 asthma
  • AZD7986 chronic obstructive pulmonary disease
  • brazikumab EXPEDITION ulcerative colitis
  • navafenterol chronic obstructive pulmonary disease
  • tozorakimab COPD/atopic dermatitis/asthma/COVID-19

Phase III

Phase III

  • brazikumab INTREPID Crohn's disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • PT027 asthma
  • Saphnelo TULIP 1 & TULIP 2 AZALEA (China) systemic lupus erythematosus
  • Tezspire (tezepelumab) NAVIGATOR DIRECTION severe uncontrolled asthma

LCM Projects

LCM Projects

  • Breztri/Trixeo (PT010) KALOS LAGOS asthma
  • Fasenra ARROYO chronic spontaneous urticaria
  • Fasenra FJORD bullous pemphigoid
  • Fasenra HILLIER atopic dermatitis
  • Fasenra MAHALE non-cystic fibrosis bronchiectasis
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra MESSINA eosinophilic esophagitis
  • Fasenra NATRON hypereosinophilic syndrome
  • Fasenra OSTRO ORCHID (China/Japan) nasal polyps
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Saphnelo lupus nephritis
  • Saphnelo TULIP-SC systemic lupus erythematosus (subcutaneous)
  • Tezspire (tezepelumab) chronic obstructive pulmonary disease
  • Tezspire (tezepelumab) WAYPOINT nasal polyps

Our Medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

Accolate, Accoleit, Vanticon


Bevespi Aerosphere

glycopyrronium/formoterol fumarate

Breztri Aerosphere

budesonide/glycopyrronium/formoterol fumarate

Bricanyl Respules


Bricanyl Turbuhaler

terbutaline in a dry powder inhaler



Duaklir Genuair


Eklira Genuair/Tudorza/Bretaris

aclidinium, a LAMA



Oxis Turbuhaler

Oxis Turbuhaler

Pulmicort Respules

budesonide inhalation suspension

Pulmicort Turbuhaler




Symbicort pMDI


Symbicort Turbuhaler


Latest news

Veeva ID: Z4-39160
Date of preparation: October 2021